What is Vycor Med Inc's earnings per share (EPS)?

Vycor Med Inc (VYCO) reported diluted earnings per share of $-0.01 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vycor Med Inc Financials

VYCO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Vycor Med Inc (VYCO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.19x

For every $1 of reported earnings, Vycor Med Inc generates $0.19 in operating cash flow (-$13K OCF vs -$72K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Adequate

2.6x

Vycor Med Inc earns $2.6 in operating income for every $1 of interest expense ($34K vs $13K). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.9M

YoY+17.2%

5Y CAGR+10.3%

10Y CAGR+5.0%

Vycor Med Inc generated $1.9M in revenue in fiscal year 2025. This represents an increase of 17.2% from the prior year.

EBITDA

$93K

YoY+85.4%

Vycor Med Inc's EBITDA was $93K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 85.4% from the prior year.

Net Income

-$72K

YoY+32.4%

Vycor Med Inc reported -$72K in net income in fiscal year 2025. This represents an increase of 32.4% from the prior year.

EPS (Diluted)

$-0.01

YoY+0.0%

Vycor Med Inc earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$19K

YoY-133.4%

Vycor Med Inc generated -$19K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 133.4% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

33M

YoY+0.0%

5Y CAGR+4.0%

10Y CAGR+11.8%

Vycor Med Inc had 33M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

83.8%

YoY-5.7pp

5Y CAGR-4.6pp

10Y CAGR-1.8pp

Vycor Med Inc's gross margin was 83.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.7 percentage points from the prior year.

Operating Margin

1.8%

YoY+2.4pp

5Y CAGR+65.5pp

10Y CAGR+176.7pp

Vycor Med Inc's operating margin was 1.8% in fiscal year 2025, reflecting core business profitability. This is up 2.4 percentage points from the prior year.

Net Margin

-3.9%

YoY+2.9pp

5Y CAGR+68.1pp

10Y CAGR+179.0pp

Vycor Med Inc's net profit margin was -3.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.9 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$10K

YoY-35.0%

10Y CAGR-17.9%

Vycor Med Inc invested $10K in research and development in fiscal year 2025. This represents a decrease of 35.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY+24.4%

5Y CAGR-39.0%

10Y CAGR-30.9%

Vycor Med Inc invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 24.4% from the prior year.

VYCO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.9M+17.2%	$1.6M+8.8%	$1.5M+19.4%	$1.2M-12.2%	$1.4M+22.0%	$1.1M
Cost of Revenue	$302K+81.2%	$167K+15.1%	$145K+3.1%	$141K+4.4%	$135K+1.7%	$132K
Gross Profit	$1.6M+9.7%	$1.4M+8.1%	$1.3M+21.6%	$1.1M-14.0%	$1.3M+24.6%	$1.0M
R&D Expenses	$10K-35.0%	$15K-32.1%	$23K	N/A	$15K	$0
SG&A Expenses	$1.5M+7.4%	$1.4M+13.5%	$1.2M-10.2%	$1.3M-17.5%	$1.6M-4.0%	$1.7M
Operating Income	$34K+470.7%	-$9K-122.8%	$40K+113.1%	-$307K+29.7%	-$436K+40.1%	-$727K
Interest Expense	$13K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$72K+32.4%	-$107K-53.8%	-$70K+82.8%	-$405K+7.1%	-$436K+47.0%	-$822K
EPS (Diluted)	$-0.010.0%	$-0.010.0%	$-0.01+50.0%	$-0.02	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$514K+3.5%	$496K+13.7%	$436K-4.1%	$455K+16.5%	$391K-3.8%	$406K+20.6%	$337K+9.3%	$308K
Cost of Revenue	$62K-23.7%	$81K+4.2%	$78K+34.6%	$58K+57.2%	$37K+4.6%	$35K-5.0%	$37K-11.9%	$42K
Gross Profit	$452K+8.8%	$415K+15.8%	$359K-9.8%	$397K+12.2%	$354K-4.6%	$371K+23.7%	$300K+12.7%	$266K
R&D Expenses	N/A	$4K-27.1%	$6K	N/A	$6K+183.9%	$2K	N/A	$2K
SG&A Expenses	$405K+17.4%	$345K-1.6%	$351K-1.6%	$357K-3.1%	$368K+8.9%	$338K+14.7%	$295K-6.1%	$314K
Operating Income	$32K-37.3%	$51K+499.4%	-$13K-166.2%	$19K+155.1%	-$35K-317.2%	$16K+269.7%	-$10K+85.1%	-$64K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$5K-79.3%	$24K+161.9%	-$39K-472.4%	-$7K+88.7%	-$60K-495.9%	-$10K+67.2%	-$31K+67.1%	-$93K
EPS (Diluted)	$0.00	$0.00+100.0%	$-0.01	N/A	$-0.01	$0.00+100.0%	$-0.01	N/A

VYCO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$998K+0.6%	$992K+15.4%	$860K-8.0%	$935K-5.2%	$987K
Current Assets	N/A	$633K+8.4%	$584K+12.8%	$518K+6.2%	$487K+5.1%	$464K
Cash & Equivalents	N/A	$106K+84.4%	$57K+54.7%	$37K-59.3%	$91K+97.7%	$46K
Inventory	N/A	$159K-31.9%	$234K-5.9%	$249K+19.9%	$208K+14.6%	$181K
Accounts Receivable	N/A	$245K+14.0%	$215K+37.8%	$156K+23.9%	$126K-20.8%	$159K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$4.7M+8.6%	$4.3M+13.6%	$3.8M+360.4%	-$1.5M-149.2%	$3.0M
Current Liabilities	N/A	$4.5M+10.4%	$4.1M+11.5%	$3.7M+16.0%	$3.1M+14.9%	$2.7M
Long-Term Debt	N/A	N/A	N/A	N/A	$150K0.0%	$150K
Total Equity	N/A	-$3.7M-11.0%	-$3.3M-13.1%	-$2.9M-222.8%	$2.4M+220.9%	-$2.0M
Retained Earnings	N/A	-$33.3M-1.3%	-$32.8M-1.2%	-$32.4M-2.3%	-$31.7M-2.5%	-$30.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$941K+7.1%	$879K-6.6%	$941K-5.7%	$998K-7.1%	$1.1M+7.8%	$997K+2.9%	$969K-2.4%	$992K
Current Assets	$663K+19.5%	$554K-7.7%	$601K-5.1%	$633K-14.9%	$743K+15.5%	$643K+9.4%	$588K+0.7%	$584K
Cash & Equivalents	$64K-35.6%	$100K+63.3%	$61K-42.2%	$106K-33.0%	$158K+32.1%	$119K+172.0%	$44K-23.4%	$57K
Inventory	$167K+7.3%	$156K-11.5%	$176K+10.6%	$159K-15.0%	$188K-14.1%	$218K-1.5%	$222K-5.3%	$234K
Accounts Receivable	$326K+60.9%	$203K-11.7%	$229K-6.5%	$245K+2.7%	$239K-5.6%	$253K+3.6%	$244K+13.4%	$215K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.0M+4.6%	$4.7M-1.8%	$4.8M+3.1%	$4.7M-1.5%	$4.8M+5.1%	$4.5M+0.9%	$4.5M+3.9%	$4.3M
Current Liabilities	$4.8M+5.1%	$4.6M-1.5%	$4.7M+3.5%	$4.5M-1.2%	$4.6M+5.7%	$4.3M+1.2%	$4.3M+4.5%	$4.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$4.0M-4.1%	-$3.9M+0.6%	-$3.9M-5.4%	-$3.7M-0.2%	-$3.7M-4.4%	-$3.5M-0.3%	-$3.5M-5.8%	-$3.3M
Retained Earnings	-$33.6M-0.5%	-$33.4M+0.1%	-$33.5M-0.6%	-$33.3M0.0%	-$33.2M-0.7%	-$33.0M0.0%	-$33.0M-0.6%	-$32.8M

VYCO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$13K-122.4%	$60K+104.2%	$29K+113.6%	-$217K-1115.6%	$21K+108.6%	-$249K
Capital Expenditures	$5K+24.4%	$4K-55.3%	$9K+237.6%	$3K-92.8%	$38K-38.2%	$62K
Free Cash Flow	-$19K-133.4%	$56K+178.9%	$20K+109.1%	-$220K-1192.5%	-$17K+94.5%	-$311K
Investing Cash Flow	-$4K-4.4%	-$4K+55.3%	-$9K-237.6%	-$3K+92.8%	-$38K+26.9%	-$52K
Financing Cash Flow	-$812+89.3%	-$8K-3680.1%	$211-99.9%	$166K+167.8%	$62K-78.4%	$287K
Dividends Paid	N/A	N/A	$324K0.0%	$324K	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$72K-255.3%	$47K+273.3%	-$27K+29.7%	-$38K-465.6%	$10K-87.8%	$86K+4459.3%	$2K-65.7%	$6K
Capital Expenditures	$1	N/A	N/A	-$1K	N/A	N/A	N/A	$6K
Free Cash Flow	-$72K	N/A	N/A	-$39K	N/A	N/A	N/A	-$396
Investing Cash Flow	$0	N/A	N/A	$170+103.4%	-$5K	$0-100.0%	$662+111.2%	-$6K
Financing Cash Flow	$37K+810.0%	-$5K+70.6%	-$18K-27.5%	-$14K-142.2%	$33K+410.5%	-$11K+33.7%	-$16K-40.6%	-$11K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VYCO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	83.8%-5.7pp	89.5%-0.6pp	90.1%+1.6pp	88.5%-1.8pp	90.3%+1.9pp	88.4%
Operating Margin	1.8%+2.4pp	-0.6%-3.3pp	2.8%+27.8pp	-25.1%+6.2pp	-31.3%+32.4pp	-63.7%
Net Margin	-3.9%+2.9pp	-6.8%-2.0pp	-4.8%+28.3pp	-33.1%-1.8pp	-31.3%+40.7pp	-72.0%
Return on Equity	N/A	N/A	N/A	N/A	-18.2%	N/A
Return on Assets	N/A	-10.7%-3.7pp	-7.0%+40.1pp	-47.1%-0.5pp	-46.6%+36.8pp	-83.4%
Current Ratio	N/A	0.140.0	0.140.0	0.14-0.0	0.15-0.0	0.17
Debt-to-Equity	N/A	-1.27+0.0	-1.300.0	-1.29-1.4	0.06+0.1	-0.08
FCF Margin	-1.0%-4.5pp	3.5%+2.2pp	1.4%+19.3pp	-18.0%-16.8pp	-1.2%+26.0pp	-27.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	88.0%+4.3pp	83.7%+1.5pp	82.2%-5.1pp	87.3%-3.3pp	90.6%-0.8pp	91.3%+2.3pp	89.0%+2.6pp	86.4%
Operating Margin	6.2%-4.1pp	10.3%+13.2pp	-2.9%-7.2pp	4.3%+13.2pp	-9.0%-13.0pp	4.0%+6.8pp	-2.8%+18.0pp	-20.8%
Net Margin	1.0%-3.9pp	4.8%+13.7pp	-8.8%-7.4pp	-1.5%+13.8pp	-15.3%-12.8pp	-2.5%+6.6pp	-9.1%+21.1pp	-30.2%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	0.5%-2.2pp	2.7%+6.8pp	-4.1%-3.4pp	-0.7%+4.9pp	-5.6%-4.6pp	-1.0%+2.2pp	-3.2%+6.2pp	-9.4%
Current Ratio	0.14+0.0	0.120.0	0.13-0.0	0.14-0.0	0.16+0.0	0.15+0.0	0.140.0	0.14
Debt-to-Equity	-1.230.0	-1.23+0.0	-1.24+0.0	-1.27+0.0	-1.290.0	-1.280.0	-1.28+0.0	-1.30
FCF Margin	-14.1%	N/A	N/A	-8.7%	N/A	N/A	N/A	-0.1%

Frequently Asked Questions

What is Vycor Med Inc's annual revenue?

Vycor Med Inc (VYCO) reported $1.9M in total revenue for fiscal year 2025. This represents a 17.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vycor Med Inc's revenue growing?

Vycor Med Inc (VYCO) revenue grew by 17.2% year-over-year, from $1.6M to $1.9M in fiscal year 2025.

Is Vycor Med Inc profitable?

No, Vycor Med Inc (VYCO) reported a net income of -$72K in fiscal year 2025, with a net profit margin of -3.9%.

What is Vycor Med Inc's EBITDA?

Vycor Med Inc (VYCO) had EBITDA of $93K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Vycor Med Inc's gross margin?

Vycor Med Inc (VYCO) had a gross margin of 83.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Vycor Med Inc's operating margin?

Vycor Med Inc (VYCO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Vycor Med Inc's net profit margin?

Vycor Med Inc (VYCO) had a net profit margin of -3.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Vycor Med Inc's free cash flow?

Vycor Med Inc (VYCO) generated -$19K in free cash flow during fiscal year 2025. This represents a -133.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vycor Med Inc's operating cash flow?

Vycor Med Inc (VYCO) generated -$13K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Vycor Med Inc's capital expenditures?

Vycor Med Inc (VYCO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Vycor Med Inc spend on research and development?

Vycor Med Inc (VYCO) invested $10K in research and development during fiscal year 2025.

How many shares does Vycor Med Inc have outstanding?

Vycor Med Inc (VYCO) had 33M shares outstanding as of fiscal year 2025.

Are Vycor Med Inc's earnings high quality?

Vycor Med Inc (VYCO) has an earnings quality ratio of 0.19x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Vycor Med Inc cover its interest payments?

Vycor Med Inc (VYCO) has an interest coverage ratio of 2.6x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.